Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186197 | 0.86 | KIF11 (0.41) | KIF11PTGES2PTPN1GRIA4CYP3A4 | |
| SCHEMBL3043018 | 0.83 | KIF11 (0.61) | KIF11CLK4CYP3A4 | |
| SCHEMBL5188424 | 0.82 | CA12 (0.42) | CA12CA1CA2CA9KIF11 | |
| SCHEMBL5187248 | 0.82 | GRIA4 (0.42) | CA12CA1CA2CA9KIF11 | |
| SCHEMBL6561643 | 0.82 | ALDH1A1 (0.39) | CA12CA1CA2CA9KIF11 | |
| SCHEMBL5187825 | 0.81 | CYP17A1 (0.46) | KIF11CNR1CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL5187343 | 0.81 | CYP3A4 (0.43) | KIF11CNR1CDK2PLK4DAPK3 | |
| SCHEMBL5186164 | 0.81 | KIF11 (0.50) | CA12CA1CA2CA9KIF11 | |
| SCHEMBL6155949 | 0.81 | KIF11 (0.50) | CA12CA1CA2CA9KIF11 | |
| SCHEMBL6155989 | 0.81 | KIF11 (0.50) | CA12CA1CA2CA9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | claimed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | claimed |
| JP-2002543177-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | claimed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1330233-B1 | METHOD OF TREATING STROKE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063680-A1 | Method of treating stroke | CLEMENS JAMES ALLEN (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1330233-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002032389-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | CA12 1905/4885CA1 748/4885CA2 647/4885 |
| US-20040063680-A1 | Method of treating stroke | ASAH2, PCSK7, PCSK9 | CA12 422/4885CA1 348/4885CA2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.